Nevro Raises $22M To Relieve Chronic Back Pain
Yesterday I asked PE Week Wire readers to name a neuromodulation startup thathas quietlyraised $45 million in new VC funding. Turns out it was a bit of a trick question, because the regulatory filing I based it on had some incorrect information. The answer – as two readers somehow guessed – is Nevro Corp. a Palo Alto-based company focused on treating patients suffering from chronic back pain (it will later move onto other chronic pain indications). The incorrect piece of info is the $45 million. Company CEO Konstantinos Alataris – a former vice president with Bay City Capital – says that the company actually raised $21.75 million in Series B funding, and will soon file an amended regulatory doc to reflect it. “Just a typo,” explains
10 September 2008•1 min read
